Literature DB >> 26754489

Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure.

Xia Li1, Jin Cheng1, Zhiguang Zhou1.   

Abstract

Type 1 diabetes (T1D) results from a chronic autoimmune process that leads to β-cell destruction and exogenous insulin dependence. The natural history of T1D proposed by Eisenbarth suggested six relatively independent stages over the course of the entire disease process, which was considered to be linear and chronic. Based on this classical theory, immunotherapies aim to prevent or reverse all these periods of β-cell loss. Over the past 30 years, much novel information about the pathogenesis of T1D proved that there are complex metabolic changes occurring throughout the entire disease process. Therefore, new possible models for the natural history of the disease have been proposed; these models, in turn, may help facilitate fresh avenues for the prevention and cure of T1D. Herein, we briefly review recent findings in this field of research, with the aim of providing a better theoretical basis for clinical practice.
© 2016 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  1型糖尿病; autoimmunity; immunotherapy; type 1 diabetes mellitus; β-cell; β细胞; 免疫治疗; 自身免疫

Mesh:

Substances:

Year:  2016        PMID: 26754489     DOI: 10.1111/1753-0407.12376

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  5 in total

1.  Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.

Authors:  Raghu Ganugula; Meenakshi Arora; Patcharawalai Jaisamut; Ruedeekorn Wiwattanapatapee; Heather G Jørgensen; Vinod P Venkatpurwar; Beiyan Zhou; Aline Rodrigues Hoffmann; Rita Basu; Shaodong Guo; Naga Venkata Ravi Kumar Majeti
Journal:  Br J Pharmacol       Date:  2017-05-30       Impact factor: 8.739

2.  Treg gene signatures predict and measure type 1 diabetes trajectory.

Authors:  Anne M Pesenacker; Virginia Chen; Jana Gillies; Cate Speake; Ashish K Marwaha; Annika Sun; Samuel Chow; Rusung Tan; Thomas Elliott; Jan P Dutz; Scott J Tebbutt; Megan K Levings
Journal:  JCI Insight       Date:  2019-03-21

3.  Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes.

Authors:  Paul M McKeigue; Athina Spiliopoulou; Stuart McGurnaghan; Marco Colombo; Luke Blackbourn; Timothy J McDonald; Suna Onengut-Gomuscu; Stephen S Rich; Colin N A Palmer; John A McKnight; Mark W J Strachan; Alan W Patrick; John Chalmers; Robert S Lindsay; John R Petrie; Sandeep Thekkepat; Andrew Collier; Sandra MacRury; Helen M Colhoun
Journal:  BMC Med       Date:  2019-08-23       Impact factor: 8.775

Review 4.  The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation.

Authors:  Rong Tang; Ting Zhong; Chao Wu; Zhiguang Zhou; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-03       Impact factor: 5.555

Review 5.  Application of Artificial Intelligence in Diabetes Education and Management: Present Status and Promising Prospect.

Authors:  Juan Li; Jin Huang; Lanbo Zheng; Xia Li
Journal:  Front Public Health       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.